research article
Targeting the Progesterone Receptor in Breast Cancer: Mind the Short Form!
March 1, 2023
The presurgical window of opportunity trial (WOT) MIPRA provides evidence that neoadjuvant treatment with the prog-esterone receptor (PR) antagonist mifepristone (RU486) may benefit patients with estrogen receptor-positive (ER+) breast cancer characterized by a high ratio of PR-A versus PR-B iso-form (>1.5), suggesting that PR may be targeted in a subset of patients. See related article by Elia et al., p. 866
Type
research article
Web of Science ID
WOS:000990190000001
Author(s)
Date Issued
2023-03-01
Publisher
Published in
Volume
29
Issue
5
Start page
833
End page
834
Subjects
Editorial or Peer reviewed
REVIEWED
Written at
EPFL
EPFL units
Available on Infoscience
June 5, 2023
Use this identifier to reference this record